المؤلفون: A. V. Vereshchagina, T. M. Uskach, O. V. Sapelnikov, V. A. Amanatova, I. R. Grishin, A. A. Kulikov, V. S. Kostin, R. S. Akchurin, А. В. Верещагина, Т. М. Ускач, О. В. Сапельников, В. A. Аманатова, И. Р. Гришин, А. А. Куликов, В. С. Костин, Р. С. Акчурин

المساهمون: The study was performed with the support of the National Medical Research Centre of Cardiology named after academician E.I. Chazov., Исследование проведено при поддержке Национального медицинского исследовательского центра кардиологии.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 18, No 4 (2022); 427-432 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 4 (2022); 427-432 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: подкожный имплантируемый кардиовертер-дефибриллятор, chronic heart failure with low ejection fraction, subcutaneous implantable cardioverter-defibrillator, хроническая сердечная недостаточность с низкой фракцией выброса

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2793/2342; Moss AJ, Hall WJ, Cannom DS, et. al. Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. New Engl J Med. 1996;335(26):1933-40. DOI:10.1056/nejm199612263352601.; Moss AJ, Zareba W, Hall WJ, et. al. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. New Engl J Med. 2002;346(12):877-83. DOI:10.1056/nejmoa013474.; Kong MH, Fonarow G C, Peterson ED, et. al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol. 2011;57(7):794-801. DOI:10.1016/j.jacc.2010.09.064.; Kaya E, Rassaf T, Wakili R. Subcutaneous ICD: Current standards and future perspective. Int J Cardiol Heart Vasc. 2019;24:100409. DOI:10.1016/j.ijcha.2019.100409.; Honarbakhsh S, Providencia R, Srinivasan N, et al. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. Int J Cardiol. 2017;228:280-5. DOI:10.1016/j.ijcard.2016.11.017.; Olde Nordkamp LO, Knops R, Bardy G, et. al. Rationale and design of the PRAETORIAN trial: a Prospective, Randomized comparison of subcutaneous and transvenous implantable cardioverterdefibrillator therapy. American heart journal. 2012;163(5):753-760. Doi:10.1016/j.ahj.2012.02.012.; Gold S MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator PostApproval Study: clinical characteristics and perioperative results. Heart Rhythm. 2017;10(14):1456-63. DOI:10.1016/j.hrthm.2017.05.016.; Kamp Nicholas J, Al-Khatib Sana M. The subcutaneous implantable cardioverter-defibrillator in review. Am Heart J. 2019;217:131-9. DOI:10.1016/j.ahj.2019.08.010.; Weiss R, Knight BP, Gold MR, et. al. Safety and efficacy of a totally subcutaneous implantablecardioverter defibrillator. Circulation. 2013;128(9):944-53. DOI:10.1161/CIRCULATIONAHA.113.003042.; Boersma L, Barr C, Knops R, et. al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol. 2017;70(7):842-4. DOI:10.1016/j.jacc.2017.06.040.; Knops RE, Olde Nordkamp LRA, Delnoy PPHM, et. al. Subcutaneous or Transvenous Defibrillator Therapy Collaborators. New Engl J Med. 2020;383:526-36. DOI:10.1056/NEJMoa1915932.; Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2018;72(2):91-220. DOI:10.1016/j.hrthm.2017.10.035.; Priori SG, Blomstrom-LundqvistC, Mazzanti A, et. al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867. DOI:10.1093/eurheartj/ehv316.; Лебедев Д.С., Михайлов Е.Н., Неминущий Н.М., и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский Кардиологический Журнал. 2021;26(7):4600. DOI:10.15829/1560-4071-2021-4600.; Larbig R, Bettin M, Motloch LJ, et al. Management of inappropriate shocks/T-wave-oversensing in S-ICD®-patients. Herzschr Elektrophys. 2018;29(1):122-6. DOI:10.1007/s00399-018-0555-1.; Rhythm Management Product Performance Report Q3 Edition 2021 [cited 2022 Jan 10]. Available from: https://www.bostonscientific.com/content/dam/bostonscientific/quality/ppr/2021/q3/Q3%202021%20CRM%20Product%20Performance%20Report%20Rev%20B.pdf.; Gold MR, Lambiase PD, El-Chami MF, et. al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021;143(1):7-17. DOI:10.1161/CIRCULATIONAHA.120.048728.; Moss AJ, Schuger C, Beck CA, et al., for the MADIT-RIT Trial, Investigators Reduction in Inappropriate Therapy and Mortality through ICD Programming. New England Journal of Medicine. 2012;367(24):2275-83. DOI:10.1056/NEJMoa1211107.; Lambiase P.D., Barr C., Theuns D.A., et. al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35(25):1657-65. DOI:10.1093/eurheartj/ehu112.; Burke MC, Gold MR, Knight BP, et. al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. Journal of the American College of Cardiology. 2015;65(16):1605-15. DOI:10.1016/j.jacc.2015.02.047.; Boersma L, Burke MC, Neuzil P, et. al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm. 2016;13(1):157-64. DOI:10.1016/j.hrthm.2015.08.039.; Knops RE, Brouwer TF, Barr CS et al. The learning curve associated with the introduction of the subcutaneous implantable defibrillator. Europace. 2016;18(7):1010-5. DOI:10.1093/europace/euv299.; https://www.rpcardio.com/jour/article/view/2793

الاتاحة: https://www.rpcardio.com/jour/article/view/2793
https://doi.org/10.20996/1819-6446-2022-08-05

المؤلفون: T. M. Uskach, O. V. Sapelnikov, A. A. Safiullina, I. R. Grishin, V. A. Amanatova, R. S. Akchurin, S. N. Tereshchenko, Т. М. Ускач, О. В. Сапельников, А. А. Сафиуллина, И. Р. Гришин, В. А. Аманатова, Р. С. Акчурин, С. Н. Терещенко

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 23, № 1 (2021); 30-37 ; Вестник трансплантологии и искусственных органов; Том 23, № 1 (2021); 30-37 ; 2412-6160 ; 1995-1191

مصطلحات موضوعية: сердечная недостаточность, фибрилляция предсердий, модуляция сердечной сократимости, фракция выброса левого желудочка, качество жизни, atrial fibrillation, modulation of heart contractility, left ventricular ejection fraction, quality of life

وصف الملف: application/pdf

Relation: https://journal.transpl.ru/vtio/article/view/1312/1081; https://journal.transpl.ru/vtio/article/view/1312/1180; Thihalolipavan S, Morin DP. Atrial fibrillation and heart failure: update 2015. Prog Cardiovasc Dis. 2015; 58 (2): 126-135. doi:10.1016/j.pcad.2015.07.004.; Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002; 13 (4): 399-405. doi:10.1046/j.1540-8167.2002.00399.x.; Ponikowski P, Voors AA, Anker SD, Bueno H, Cle -land JG, Coats AJ et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016; 37 (27): 2129-2200. doi:10.1093/eurheartj/ehw128.; Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS et al. ESC-HFA HF Long-Term Registry Investigatorset al; Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39 (48): 4277-4284. doi:10.1093/eurheartj/ehy626.; Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24: 442-463. doi:10.1016/s0195-668x(02)00823-0.; Wijesurendra RS, Casadei B. Atrial fibrillation: effects beyond the atrium? Cardiovasc Res. 2015; 105: 238247. doi:10.1093/cvr/cvv001.; Ziff OJ, Carter PR, McGowan J, Uppal H, Chandran S, Russell S et al. The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: insights from the United Kingdom ACALM registry. Int J Cardiol. 2018; 252: 117121. doi:10.1016/j.ij-card.2017.06.033.; Lardizabal JA, Deedwania PC. Atrial fibrillation in heart failure. Med Clin North Am. 2012; 96: 987-1000. doi:10.1016/j.mcna.2012.07.007.; Roy D, Talajic M, Nattel S, Wyse D G, Dorian P, Lee KL et al. Atrial Fibrillation and Congestive Heart Failure. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358: 2667-2677. doi:10.1056/NEJMoa0708789.; Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008; 359: 17781785. doi:10.1056/NEJMoa0708234.; Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al. CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417427. doi:10.1056/NEJ-Moa1707855.; Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2020 Aug; 00: 1-126. doi:10.1093/eurheartj/ehaa612.; Huang W, Su L, Wu S. Pacing treatment of atrial fibrillation patients with heart failure: His bundle pacing combined with atrioventricular node ablation. Card Electrophysiol Clin. 2018; 10: 519535. doi:10.1016/j.ccep.2018.05.016.; Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E et al. APAF-CRT Investigators. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018; 39: 3999-4008. doi:10.1093/eur-heartj/ehy555.; Abi-Samra F, Gutterman D. Cardiac contractility modulation: a novel approach for the treatment of heart failure. Heart Fail Rev. 2016; 21 (6): 645-660. doi:10.1007/s10741-016-9571-6.; Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21 (10): 1169-1186. doi:10.1002/ejhf.1531.; Tint D, Florea R, Micu S. New Generation Cardiac Contractility Modulation Device-Filling the Gap in Heart Failure Treatment. J Clin Med. 2019 Apr 29; 8 (5): 588. doi:10.3390/jcm8050588. doi:10.3390/jcm8050588.; Ревишвили АШ, Артюхина ЕА, Амирасланов АЮ, Васковский ВА, Яшков МВ, Купцов ВВ и др. Первый опыт лечения пациентов с хронической сердечной недостаточностью методом имплантации устройств, модулирующих сокращения сердца. Вестник аритмологии. 2017; (90): 12-18.; Ускач ТМ, Сафиуллина АА, Сапельников ОВ, Амана-това ВА, Николаева ОА, Гришин ИР и др. Модуляция сердечной сократимости у пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий. Терапевтический архив. 2020; 92 (9): 8-14. doi:10.26442/00403660.2020.09.000598.; Mando R, Goel A, Habash F, Saad M, Ayoub K, Vallurupalli S et al. Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Hindawi Cardiovascular Therapeutics. 2019; 2019, Article ID 9769724: 10. doi:10.1155/2019/9769724.; Anker SD, Borggrefe M, Neuser H, Ohlow M-A, Roger S, Goette A et al. Cardiac Contractility Modulation Improves Long-Term Survival and Hospitalizations in Heart Failure With Reduced Ejection Fraction. Eur J Heart Fail. 2019 Sep; 21 (9): 1103-1113. doi:10.1002/ejhf.1374.; https://journal.transpl.ru/vtio/article/view/1312

الاتاحة: https://journal.transpl.ru/vtio/article/view/1312
https://doi.org/10.15825/1995-1191-2021-1-30-37